ConductScience.org, home

Trial · NCT03645395

Results by group24

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Part 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs) and Dose-limiting ToxicityPart 1: MT-3724 10 mcg/Kg-LENTEAEs3participants
Part 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs) and Dose-limiting ToxicityPart 1: MT-3724 25 mcg/Kg-LENTEAEs3participants
Part 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs) and Dose-limiting ToxicityPart 1: MT-3724 20 mcg/Kg-LENTEAEs3participants
Part 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs) and Dose-limiting ToxicityPart 1: MT-3724 10 mcg/Kg-LENSAEs1participants
Part 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs) and Dose-limiting ToxicityPart 1: MT-3724 25 mcg/Kg-LENSAEs1participants
Part 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs) and Dose-limiting ToxicityPart 1: MT-3724 20 mcg/Kg-LENSAEs1participants
Part 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs) and Dose-limiting ToxicityPart 1: MT-3724 10 mcg/Kg-LENDLT0participants
Part 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs) and Dose-limiting ToxicityPart 1: MT-3724 25 mcg/Kg-LENDLT2participants
Part 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs) and Dose-limiting ToxicityPart 1: MT-3724 20 mcg/Kg-LENDLT0participants
Part 1 and 2: Number of Participants With Abnormal Laboratory ParametersPart 1: MT-3724 10 mcg/Kg-LEN3Participants
Part 1 and 2: Number of Participants With Abnormal Laboratory ParametersPart 1: MT-3724 25 mcg/Kg-LEN3Participants
Part 1 and 2: Number of Participants With Abnormal Laboratory ParametersPart 1: MT-3724 20 mcg/Kg-LEN3Participants
Part 1 and 2: Plasma Concentrations of MT-3724Part 1: MT-3724 10 mcg/Kg-LENNAStandard Deviation NAMicrograms per milliliter
Part 1 and 2: Plasma Concentrations of MT-3724Part 1: MT-3724 25 mcg/Kg-LENNAStandard Deviation NAMicrograms per milliliter
Part 1 and 2: Plasma Concentrations of MT-3724Part 1: MT-3724 20 mcg/Kg-LENNAStandard Deviation NAMicrograms per milliliter
Part 1 and 2: Change From Baseline in B-cell CountPart 1: MT-3724 10 mcg/Kg-LENNAStandard Deviation NAGiga cells per liter
Part 1 and 2: Change From Baseline in B-cell CountPart 1: MT-3724 25 mcg/Kg-LENNAStandard Deviation NAGiga cells per liter
Part 1 and 2: Change From Baseline in B-cell CountPart 1: MT-3724 20 mcg/Kg-LENNAStandard Deviation NAGiga cells per liter
Part 1 and 2: Number of Participants With Objective Response Rate (ORR)Part 1: MT-3724 10 mcg/Kg-LENPR2participants
Part 1 and 2: Number of Participants With Objective Response Rate (ORR)Part 1: MT-3724 25 mcg/Kg-LENPR0participants

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03645395/results